Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Eleda in connection with the acquisition of Göteborg Mark och Betong Entreprenad AB
Mandate

Vinge advises Eleda in connection with the acquisition of Göteborg Mark och Betong Entreprenad AB

January 13, 2021 Employment and Benefits Corporate Crime & Compliance Real Estate and Construction M&A General Corporate

Vinge has advised Eleda Infra Services Group (“Eleda”) on the acquisition of Göteborg Mark och Betong Entreprenad AB (“GMB”).

GMB is based in Gothenburg and provides construction and contracting services related to infrastructure, foundation and fine planning work as well as both cast-in-place and prefabricated concrete. GMB has a total approximate revenue of SEK 220 million and around 30 employees.

Vinge’s team consisted primarily of partner Christina Kokko and associates Michaela Cronemyr and Carl Fredrik Wachtmeister (M&A), Isak Willborg (Agreements), Ebba Svenburg (Employment), Frida Ställborn (Real Property & Environment), Tove Lövgren Frisk (Compliance) and Carl Bruneheim (VDR-specialist).

Related

Vinge has advised Morrow Bank AB (publ) in conjunction with the acquisition of MedMera Bank AB

 Vinge has advised Morrow Bank AB (publ) in conjunction with the acquisition of all shares in MedMera Bank AB from Kooperativa Förbundet for a total consideration of SEK 1,960 million. The transaction positions Morrow Bank as a leading Nordic platform in consumer finance with combined gross loans of SEK 28.2 billion.
March 24, 2026

Vinge advises NEWS, a portfolio company of Litorina, in connection with the sale of Skandinavisk Kommunalteknik, FANN VA-Teknik and Alunda Polyeten to Wienerberger AG

 Vinge advises Northern Environmental and Water Solutions AB (“NEWS”), a portfolio company of Litorina, in connection with the sale of the operating subsidiaries Skandinavisk Kommunalteknik, FANN VA-Teknik and Alunda Polyeten to Wienerberger AG (Vienna Stock Exchange: WIE). The transaction is expected to be completed in Q2 2026.
March 24, 2026

Vinge has advised Hansa Biopharma in connection with entering into a financing agreement

 Vinge has advised Hansa Biopharma AB (publ), a commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life-altering treatments for patients with rare immunological conditions, listed on Nasdaq Stockholm, in connection with a U.S. convertible note purchase agreement comprising USD 30 million aggregate principal amount of unsecured convertible senior notes.
March 23, 2026